Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effe
Chimerix ( NASDAQ:CMRX ) Full Year 2023 Results Key Financial Results Net loss: US$82.1m (down by 148% from US$172.2m...
Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call Transcript February 29, 2024 Chimerix, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.23. CMRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to […]